NOTICES

EXTRAMURAL RESEARCHERS' FINANCIAL CONFLICTS OF INTEREST .......................... 1
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

DATED ANNOUNCEMENTS (RFPs AND RFAs)

ANALYTICAL CHEMISTRY OF CHEMICALS AND PHARMACEUTICAL PRODUCTS
FOR TREATMENT OF INFECTIOUS DISEASES (RFP) ........................................... 1
National Institute of Allergy and Infectious Diseases
Index: ALLERGY, INFECTIOUS DISEASES

DEVELOPMENT AND MANUFACTURE OF DOSAGE FORMS OF COMPOUNDS WITH
POTENTIAL FOR TREATING INFECTIOUS DISEASES (RFP) .................................. 2
National Institute of Allergy and Infectious Diseases
Index: ALLERGY, INFECTIOUS DISEASES

NOTICE - SURVEILLANCE EPIDEMIOLOGY AND END RESULTS (SEER) (RFP) ............. 2
National Cancer Institute
Index: CANCER

ACADEMIC RESEARCH ENHANCEMENT AWARD ...................................................... 3
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

CORE GRANTS FOR CLINICAL NUTRITION RESEARCH UNITS (CNRUs) (RFA) ............ 4
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute on Aging
Index: DIABETES, DIGESTIVE AND KIDNEY DISEASES, AGING

MENTAL HEALTH SERVICES RESEARCH DEMONSTRATION GRANTS (RFA) ................. 6
National Institute of Mental Health
Index: MENTAL HEALTH

NEW APPROACHES TO STUDYING EPSTEIN-BARR VIRUS ONCOGENESIS (RFA) ............. 6
National Cancer Institute
Index: CANCER

DEVELOPMENT OF SOMATIC CELL GENE THERAPY APPROACHES FOR SPECIFIC
INBORN METABOLIC DISEASES (RFA) .............................................................. 8
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES, DIGESTIVE AND KIDNEY DISEASES
NOTICES

EXTRAMURAL RESEARCHERS' FINANCIAL CONFLICTS OF INTEREST

P.T. 34; K.W. 1014004, 1014006

National Institutes of Health

Growing expressions of public concerns suggest that NIH act to limit possibilities for actual or apparent financial conflicts of interest by investigators in research and development projects funded by NIH extramural awards. Of particular concern are circumstances that might affect investigators' objectivity, or where researchers might unduly influence, or might be perceived to influence, NIH-funded R&D projects in directions favorable to personal financial interests of themselves, their spouses, children, close professional associates, or organizations where they have appointments or other relationships.

NIH expects that participating investigators and consultants will not have financial interests in organizations or entities that produce drugs, devices, or other interventions studied in a controlled clinical trial. NIH therefore intends to take steps to develop appropriate guidance for such relationships. Guidelines would seek to outline pertinent types of research situations and personal financial interests. In accord with the PHS Grants Policy Statement, January 1, 1987, revision, concerning Standards of Conduct for Employees for awardee organizations, and to define appropriate distributions of governance between NIH and awardee organizations. Guidelines should also recognize special conditions under which restrictions should be waived to permit investigators with unusual skills and expertise to conduct studies which might otherwise be proscribed. (These guidelines should not concern financial benefits resulting from logical steps in product research/development/testing under NIH awards, e.g., Small Business Innovation Research.)

NIH encourages preliminary comments from parties wishing to suggest points to be included in this future guidance. Please address your remarks within 30 days of this publication to:

Dr. Katherine L. Bick
Deputy Director for Extramural Research
National Institutes of Health
Shannon Building, Room 144
Bethesda, Maryland 20892

Further opportunity for comments will be provided following subsequent notices in the NIH Guide for Grants and Contracts.

DATED ANNOUNCEMENTS (RFPs AND RFAs)

ANALYTICAL CHEMISTRY OF CHEMICALS AND PHARMACEUTICAL PRODUCTS FOR TREATMENT OF INFECTIOUS DISEASES

RFP AVAILABLE: RFP-NIH-NIAID-AIDSP 89-14

P.T. 34; K.W. 1003008, 0740025

National Institute of Allergy and Infectious Diseases

The purpose of the solicitation is to provide analytical chemistry support to the drug discovery effort for the treatment of infectious diseases in the areas of method development and control of chemical and pharmaceutical quality. Responsibilities of the contractor will include: characterization of the identity of the drug substance; preformulation determinations of compound solubility and stability; analysis of pharmaceutical dosage forms; and extensions of the methodologies to the detection of the drug in selected biological fluids.

This announcement is a new solicitation. The issuance of the RFP will be on January 26, 1989, and proposals will be due COB on March 29, 1989.

This NIAID-sponsored project will take approximately five years to complete. A cost-reimbursement contract is anticipated and the Institute expects to make one award.
Requests for the RFP should be directed in writing to:

Mr. Charles Hayes  
Contract Management Branch  
Westwood Building, 5333 Westbard Avenue, Room 707  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-0349

To receive a copy of the RFP, please supply this office with two (2) self-addressed mailing labels. All responsible sources may submit a proposal which will be considered.

This advertisement does not commit the Government to award a contract.

DEVELOPMENT AND MANUFACTURE OF DOSAGE FORMS OF COMPOUNDS WITH POTENTIAL FOR TREATING INFECTIOUS DISEASES

RFP AVAILABLE: RFP-NIH-NIAID-AIDSP-89-12

P.T. 34; K.W. 0740025, 0740020

National Institute of Allergy and Infectious Diseases

The purpose of this solicitation is to provide a pharmaceutical research and development capability to permit further evaluation of compounds in animal models of infectious diseases, in pharmacological disposition studies in laboratory animals, in toxicological investigations and in clinical trial. Dosage form development and manufacturing capabilities will be needed for sterile small volume parenteral freeze dried and liquid dosage forms, tablets, and capsules. Quality control testing of ingredients in the formulation and of the final product will be required. Manufactured batches will be prepared in accord with FDA's current good manufacturing practice regulations. Anticipated annual requirements are one or two drugs requiring development of injectable and of oral dosage forms, one or two injectable batches of about 4000 vials each, and two of three table/capsule batches of 50,000 units/lot.

This announcement is a new solicitation. The issuance of the RFP will be on January 25, 1989, and proposals will be due COB March 28, 1989.

This NIAID sponsored project will take approximately five years to complete. A cost-reimbursement contract is anticipated and the Institute expects to make one award.

Requests for the RFP should be directed in writing to:

Ms. Mary Anne Glitz  
Contract Management Branch  
Westwood Building, 5333 Westbard Avenue, Room 707  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-1642

To receive a copy of the RFP, please supply this office with two (2) self-addressed mailing labels. All responsible sources may submit a proposal which will be considered.

This advertisement does not commit the Government to award a contract.

NOTICE - SURVEILLANCE EPIDEMIOLOGY AND END RESULTS (SEER)


P.T. 34; K.W. 0785055, 0755018, 0715035

National Cancer Institute

The Division of Cancer Prevention and Control, National Cancer Institute, intends to negotiate with the Connecticut Department of Health Services, the Commonwealth of Puerto Rico Department of Health, Emory University, Fred Hutchinson Cancer Research Center, Michigan Cancer Foundation, New Jersey Dept. of Health, Northern California Cancer Center, Research Corporation of
the University of Hawaii, University of Iowa, University of New Mexico, and the University of Utah for a seven-year continuation contract for the Surveillance, Epidemiology and End Results (SEER) Program. The project includes collecting and reporting on population-based cancer incidence, treatment and survival data for the United States. (Authority: 41 U.S.C. 253 (c) (1), as set forth in FAR 6.302-1 and HHSAR 306.302.-1.) Only one responsible source and no other supplies or services will satisfy agency requirements. In accordance with FAR 6.302-1 (a) (2) (ii) and HHSAR 306.302(a) (2) (ii), services may be deemed to be available only from the original sources for follow-on contracts for continued development. Inherent duplication of cost to the Government and unacceptable delays in completing this follow-up project make competition unfeasible for this project. The above named organizations have the prerequisite knowledge, experience and facilities for continued performance of the proposed tasks by virtue of their preliminary and current work on these projects. For Informational Purposes Only. RFP is not available. For further information contact:

Shirley Kyle
Contracting Officer
Prevention and Cancer Control Section, RCB
National Cancer Institute, NIH
Executive Plaza South, Suite 635
Bethesda, Maryland 20892
Telephone: (301) 496-8603

ACADEMIC RESEARCH ENHANCEMENT AWARD
P.T. 34; K.W. 0710030, 1014002, 1014006

National Institutes of Health
Application Receipt Date: June 22, 1989

The National Institutes of Health (NIH) is making a special effort to stimulate research in educational institutions which provide the baccalaureate training for a significant number of our nation's research scientists but which historically have not been major recipients of NIH support. Since Fiscal Year (FY) 1985, Congressional appropriations for the NIH have included funds for this initiative, which NIH has implemented through the Academic Research Enhancement Award (AREA) Program. In FY 85, the NIH made 75 awards, totalling $5 million. In FY 86, 146 such grants were awarded, amounting to $9.57 million. In FY 87, a total of 152 AREA grants were awarded from the Congressional appropriation of $10 million. In FY 88, 173 awards were made, totalling approximately $11 million.

This award is designed to enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds. The AREA funds are intended to support new research projects or expand ongoing research activities proposed by faculty members of these institutions in areas related to the health sciences. Applications for FY 1989 AREA grants are currently undergoing review for scientific merit. Since it is anticipated that additional funds will be available next year, the NIH is inviting grant applications for the FY 1990 competition for AREA grants.

Eligibility requirements of the AREA Program include the following:

Applicant Institutions

o All domestic institutions offering baccalaureate or advanced degrees in the sciences related to health are eligible, except those that have received an NIH Biomedical Research Support Grant (BRSG) of $20,000 or more per year for four or more years during the period from FY 1982 through FY 1988.

o Health professional schools (e.g., schools of medicine, dentistry, nursing, osteopathy, pharmacy, veterinary medicine, public health, allied health and optometry) as well as organizationally discrete campuses of a university system are eligible if they meet the above criterion.

o Multiple applications proposing different research projects may be submitted by an applicant institution.

Applicant Principal Investigators

o Must not have active research grant support (including an AREA) from either NIH or the Alcohol, Drug Abuse and Mental Health Administration (ADAMHA) at the applicant institution at the time of award of an AREA grant.
May not submit a regular NIH or ADAMHA research grant application for essentially the same project as a pending AREA application.

Are expected to conduct the majority of their research at their own institution, although limited access to special facilities or equipment at another institution is permitted.

May not be awarded more than one AREA grant at a time nor be awarded a second AREA grant to continue the research initiated under the first AREA grant.

Those in doubt about eligibility should consult their institution's Office of Sponsored Research, or the Director, Special Programs and Initiatives (Building 31, Room 1B54, NIH, Bethesda, MD 20892, 301/496-1968).

Funding decisions will be based on the proposed research project's scientific merit and relevance to NIH programs, and the institution's contribution to the undergraduate preparation of doctoral-level health professionals. Among projects of essentially equivalent scientific merit and program relevance, preference will be given to those submitted by institutions that have granted baccalaureate degrees to 25 or more individuals who, during the period 1978-1988, obtained academic or professional doctoral degrees in the health related sciences.

AREAgs are awarded on a competitive basis. Applicants may request support for up to a total of $75,000 in direct costs (plus applicable indirect costs) for a period not to exceed 36 months. Although this award is non-renewable, it will enable qualified individual scientists within the eligible institutions to receive support for feasibility studies, pilot studies and other small-scale research projects preparatory to seeking more substantial funding from the regular NIH research grant programs. Applications for this award will be accepted under the regular application submission procedures of the Division of Research Grants (DRG) of NIH. Grant applications must be prepared and submitted on Form PHS 398 (Rev. 9/86). An abbreviated format and simplified instructions will be provided upon request to the Office of Grants Inquiries (see address below) for use in preparing these applications. The receipt date is June 22, 1989.

Those individuals and institutions meeting eligibility requirements and wishing to receive further information and/or application materials should write to:

AREA
Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building, Room 449
Bethesda, Maryland 20892
Telephone: (301) 496-7441

CORE GRANTS FOR CLINICAL NUTRITION RESEARCH UNITS (CNRUs)

RFA AVAILABLE: 89-DK-02

P.T. 34; K.W. 0710095, 0710030

National Institute of Diabetes and Digestive and Kidney Diseases
National Institute on Aging
Application Receipt Date: April 12, 1989

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute on Aging (NIA) invite applications for Clinical Nutrition Research Unit (CNRU) grants to be awarded in Fiscal Year 1990. The award of up to two CNRU grants is anticipated in Fiscal Year 1990.

A CNRU is an integrated array of research, educational, and service activities that is oriented toward human nutrition in health and disease. A research core center grant is awarded to facilitate the planning and coordination of the activities of the CNRU primarily by providing funding for core facilities and associated staff that serve the various projects of the CNRU on a shared basis.
A CNRU, at a minimum, must comprise the following seven components which also should have other sources of support such as a regular NIH research grant (RO1), NIH FIRST Award (R29), NIH Program Project (P01), NIH Individual Fellowship (F32), and the NIH Institutional National Research Service Award (T32) or other Federal and non-federal sources:

1. Research with human subjects and populations;
2. Laboratory investigations;
3. Research training (funds to be derived from other sources*);
4. Shared facilities and research services;
5. Education programs for medical students, house staff, practicing physicians, and allied health personnel (funds to be derived from other sources*); 
6. Research components of nutritional support services; and 
7. Public information activities (funds to be derived from other sources*).

* Funds to support these components may not be requested as part of an application in response to this announcement.

Potential applicants are urged to submit a letter of intent that provides a descriptive title, names of investigators involved and other participating institutions regarding their application. The letter of intent is non-binding and is not a precondition for an award and should be submitted by February 15, 1989, to Dr. Bain at the address below. In addition, the general description of a Core Center, copies of Core Center Guidelines, a more detailed RFA and consultation may be obtained from:

Van S. Hubbard, M.D., Ph.D. 
Director, Clinical Nutrition Research Units 
Westwood Building, Room 3A18B 
5333 Westbard Avenue 
Bethesda, Maryland 20892 
Telephone: (301) 496-7823 

Ralph L. Bain, Ph.D. 
Program Director for Digestive Diseases Centers Program 
Westwood Building, Room 3A16 
5333 Westbard Avenue 
Bethesda, Maryland 20892 
Telephone: (301) 496-6045

For information concerning NIA research interests in nutrition contact:

Ann Sorenson, Ph.D. 
Program Director for the NIA Nutrition Program 
Building 31, Room 5C-21 
9000 Rockville Pike 
Bethesda, Maryland 20892 
Telephone: (301) 496-1033

Applications for the CNRU Core Center grant will be evaluated in national competition by the NIH grant peer review process. The receipt of two competitive continuation applications is anticipated. Applications will be reviewed initially by a special review committee convened by the NIDDK and subsequently by the National Diabetes and Digestive and Kidney Diseases Advisory Council and/or the National Institute on Aging's Advisory Council. The special single receipt date for submissions in response to this announcement is April 12, 1989, with earliest funding December 1989. Applications are unlikely to be reviewed by a site visit team; therefore, the written application should be complete so as to facilitate review without a site visit. Extensive additional material submitted subsequent to the stated receipt date will not be accepted.

The RFA label available in the 9/86 revision of Application Form 398 must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review. Complete line 2 of the application face page with the title of this RFA, "Core Grants for Clinical Nutrition Research Units (CNRLs)," and the RFA number 89-DK-02.
MENTAL HEALTH SERVICES RESEARCH DEMONSTRATION GRANTS
(COMMUNITY SUPPORT PROGRAM FOR ADULTS)

RFA AVAILABLE: MH-88-11

P.T. 34; K.W. 0715095, 0403004

National Institute of Mental Health

Application Receipt Date: April 10, 1989

The National Institute of Mental Health (NIMH) requests applications for research demonstration grants to evaluate the effectiveness and generalizability of various approaches to case management services, community crisis-response services, and psychiatric rehabilitation services. The purpose is to generate new knowledge on effective, replicable approaches to providing the three service components and to begin building the infrastructure required to conduct future systematic research on community support services. Only State mental health authorities are eligible to apply; they may submit only one application for one project under this RFA. In 1989, it is estimated that the community support program will fund a total of approximately 8-12 projects averaging $250-350,000 per year in the three service areas.

NIMH will accept applications in response to this RFA under the receipt date of April 10, 1989.

Potential applicants wishing to seek further information should contact:

Neil Brown, Chief,
Community Support and Advocacy Branch

or

Jacqueline Parrish, Program Director
Community Support Program
Division of Education and Service Systems Liaison
National Institute of Mental Health
Parklawn Building, Room 11C-22
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-3653

NEW APPROACHES TO STUDYING EPSTEIN-BARR VIRUS ONCOGENESIS

RFA AVAILABLE: 89-CA-08

P.T. 34; K.W. 0715035, 0715125, 1002045, 1002008, 0760045

National Cancer Institute

Application Receipt Date: August 3, 1989
Letter of Intent Receipt Date: June 3, 1989

I. INTRODUCTION

Epstein-Barr virus (EBV) has been associated with several neoplasias, including Burkitt's lymphoma and nasopharyngeal carcinoma and with several infectious diseases, including infectious mononucleosis and severe chronic infectious mononucleosis. Recent evidence appears to link EBV with parotid gland tumors and B-cell lymphomas in immunosuppressed individuals. In vivo studies of EBV oncogenesis are complicated by the long interval between primary infection and the occurrence of neoplasia; and by the high prevalence of EBV infection in geographic areas where a high frequency of EBV-associated neoplasias occurs: e.g., in the malaria belt in Africa in the case of Burkitt's lymphoma, and in the Far East in the case of nasopharyngeal carcinoma. In vitro studies of EBV have been hampered by the lack of a lytic infection system. Studies have focused on lymphocytes which have been immortalized/transformed by EBV infection and in which a limited set of viral gene products are expressed. The application of recombinant DNA technology to this system has led to progress in elucidating the structure of the viral genome, further definition of viral gene products, and identification of several regulatory regions of the viral genome. However, the viral and host factors determining the disease manifestations and clinical outcomes for EBV infections are as yet undefined. Additionally, both B-cells and epithelial cells appear to be sites of viral latency and replication. While a number of investigators are studying specific aspects of EBV replication and tumorigenesis, delineation of viral and host factors which may determine the outcome of individual EBV infections has been difficult to approach directly.
The present RFA is for a single competition with a deadline of August 3, 1989 for receipt of applications, and June 3, 1989 for receipt of letters of intent. Applications should be prepared and submitted in accordance with the aims and requirements described in the complete RFA document which may be obtained from the program director listed in Section IV below.

II. RESEARCH GOALS AND SCOPE

The overall thrust of this RFA is to stimulate research on the mechanism(s) of EBV oncogenesis by developing and using new methodological approaches to overcome the difficulties inherent in EBV research. Examples of research objectives (which are not all inclusive) would include the following: (i) use of novel methods and probes to define RNA transcripts unique to or with clinical significance for different EBV neoplasias; (ii) use of new approaches to alter (mutate) the viral genome followed by the study of the effect of altered genes on viral oncogenesis; (iii) use of cell lines expressing individual EBV gene products (both structural and regulatory) to define viral genes and assess their role in the neoplastic process; (iv) use of specific reagents such as monoclonal antibodies to viral gene products to determine the role of regulatory and structural EBV proteins in the neoplastic process; (v) measurement of host response to individual viral proteins with the goal of delineating differences in the host response in specific EBV-associated neoplasias; (vi) delineation of differences in cell-mediated responses in individuals with different EBV neoplasias; and (vii) exploitation of EBV's unique pathologic aspects, such as the use of the CR-2 receptor and the activation of B-cells during the infectious process, to develop approaches to alter these unique aspects of EBV pathogenesis with the ultimate aim of preventing or reversing neoplastic conversion.

Where appropriate, collaborative arrangements to facilitate the achievement of research goals should be considered.

Applications should contain as goals both methodological development and application to a specific area of EBV oncogenesis; basic and/or clinical issues are considered as appropriate subjects for this RFA.

Furthermore, in studies involving differences between various EBV-associated neoplasias, investigators should consider not only the classical EBV-associated neoplasias, such as Burkitt's lymphoma and nasopharyngeal carcinoma, but also give some emphasis to newer EBV-related neoplasias such as EBV lymphomas in immunocompromised individuals, EBV tumors in other areas of the oropharynx such as the parotid gland, and other new EBV-associated diseases such as hairy leukoplakia.

III. MECHANISM OF SUPPORT

This RFA will use the National Institutes of Health (NIH) grant-in-aid. Responsibility for the planning, direction and execution of the proposed project will be solely that of the applicant. Except as stated in this RFA, awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement, DHHS Publication No. (OASH) 82–50,000, revised January 1, 1987.

This RFA is a one-time solicitation. Generally future unsolicited competing renewal applications will compete as research project applications with all other investigator-initiated applications and be reviewed in a standing Division of Research Grants study section. However, should the NCI determine that there is a sufficient continuing program need, NCI may announce a request for renewal applications.

Approximately $850,000 in total costs per year for five (5) years will be committed to specifically fund applications which are submitted in response to the RFA. It is anticipated that (4) to five (5) awards will be made. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. The total project period for applications submitted in response to the present RFA should not exceed five (5) years. The earliest feasible start date for the initial awards will be April 1, 1989. Although this program is provided for in the financial plans of the National Cancer Institute (NCI), award of grants pursuant to this RFA is contingent upon the availability of funds for this purpose. Non-profit and for-profit institutions are eligible to apply. Foreign as well as domestic institutions are eligible.

IV. INQUIRIES

A copy of the complete RFA describing the research goals and scope, the review criteria, and the method of applying can be obtained by contacting:
Dr. Susan B. Spring  
Program Director  
DNA Virus Studies I  
Biological Carcinogenesis Branch  
Division of Cancer Etiology  
National Cancer Institute  
Executive Plaza North, Room 540  
Bethesda, Maryland 20892  
Telephone: (301) 496-4533

Written or telephone inquiries concerning the objectives and scope of this RFA or inquiries about whether or not specific proposed research would be responsive are encouraged and should be directed to Dr. Susan B. Spring at the above address. The program director welcomes the opportunity to clarify any issues or questions from potential applicants.

DEVELOPMENT OF SOMATIC CELL GENE THERAPY APPROACHES FOR SPECIFIC INBORN METABOLIC DISEASES

RFA AVAILABLE: 89-DK-04

P.T. 34; K.W. 0715135, 1002058, 0780015, 0755020

National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt Date: July 15, 1989

INTRODUCTION AND BACKGROUND

The Metabolic Diseases and the Cystic Fibrosis Research Programs, Division of Diabetes, Endocrinology and Metabolic Diseases, support basic and clinical research and research training related to the etiology, diagnosis, prevention and treatment of inborn metabolic diseases such as: cystic fibrosis (CF), other diseases of transport, aminoacidemias, organic acidurias, lysosomal storage diseases, diseases of purine and pyrimidine metabolism, glycogen storage diseases, diseases of copper metabolism, hereditary amyloidosis, etc. This initiative is an important component of a broad program for the development or improvement of therapies for orphan diseases. This initiative is intended to encourage qualified scientists to submit regular research project grant (R01) or program project grant (P01) applications which propose novel studies to facilitate development of approaches to somatic cell gene therapy. For the purposes of this program gene therapy is defined as a molecular genetic therapeutic approach that utilizes somatic cell gene transfer to correct or ameliorate the inborn error.

OBJECTIVES AND SCOPE

This program is intended to encourage submission of proposals to develop approaches to human gene therapy for inborn metabolic diseases. Areas of research are not limited to the following: development of more efficient and more rapid approaches to chromosomal localization of relevant genes; identification and characterization of retroviral and other vectors suitable for gene transfection; development of efficient gene transfection techniques; development of techniques for homologous recombination of transfected gene/s and the host chromosome in cells, or mice or other animals that serve as models for specific metabolic diseases; development of cell lines and/or mouse models suitable for gene therapy studies; development of techniques for isolation and maintenance of host cells suitable for gene therapy; and introduction of the transfected cell into the relevant target organs of an animal model and the study of in vivo expression of the functional protein.

This program is intended to stimulate basic research and development of techniques focused on achieving successful human gene therapy. In this regard, studies on the general mechanisms of recombination and transfection are not suitable.

MECHANISM OF SUPPORT

The mechanism of support for this program will be the grant-in-aid (R01) and the program project grant (P01). Although this solicitation is included in the funding plans for Fiscal Year 1990 for NIDDK, support is contingent upon actual availability of appropriated funds. The NIDDK plans to designate a total of $2.0 million (direct and indirect costs) for the support of applications submitted in response to this solicitation; however, the amounts to be awarded will depend upon the overall merit, budget, and scope of the
applications received. It is anticipated that approximately 5 to 10 grants will be awarded under this solicitation.

APPLICATION AND REVIEW PROCEDURES

Applications must be submitted on Form PHS 398 (revised 9/86), available at most institutional business offices or from the Division of Research Grants, NIH. To identify the application as a response to this RFA, please check "Yes" on item two of page one of the application and enter "NIDDK-RFA-89-DK-04 on "Somatic Cell Gene Therapy Approaches". The RFA label (found in the 9/86 revision of application form PHS 398) must be affixed to the bottom of the face page of the original copy of the application. Applications received in response to this solicitation will be reviewed in accord with the usual NIH peer review procedures. It is expected that site visits will not be conducted and therefore the submitted applications should be complete and stand alone for purposes of review.

If an application submitted in response to this RFA is identical to a research grant application already submitted to the NIH for review, the applicant will be asked to withdraw the pending application before the new one is accepted. Simultaneous submission of identical applications will not be allowed. Both a PO1 application and the projects which are components of this PO1 may not be submitted simultaneously in response to this RFA.

A single reply date of July 15, 1989, will be strictly enforced. An anticipated schedule for review and award is detailed below:

<table>
<thead>
<tr>
<th>APPLICATION RECEIPT</th>
<th>INITIAL REVIEW</th>
<th>COUNCIL REVIEW</th>
<th>EARLIEST START DATE</th>
</tr>
</thead>
</table>

The original and four copies of the application should be sent to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland 20892XX

Two additional copies of the application are to be sent to:

Review Branch
National Institute of Diabetes and Digestive
and Kidney Diseases, NIH
Westwood Building, Room 406
Bethesda, Maryland 20892

CONSULTATION WITH PROGRAM STAFF

Prospective applicants are encouraged to request a copy of the complete RFA and to discuss their ideas with Program staff (see below) to determine whether they fit guidelines of this RFA. Applicants who intend to submit PO1 applications should request a copy of NIDDK's guidelines for program project grants.

Robert Katz, Ph.D.
Director, Metabolic Diseases
Research Program, NIDDK
Westwood Building, Room 607A
Bethesda, Maryland 20892
Telephone: (301) 496-7997

Nancy Lamontagne, Ph.D.
Director, Cystic Fibrosis
Program, NIDDK
Westwood Building, Room 607
Bethesda, Maryland 20892
Telephone: (301) 496-4980

This program is described in the Catalog of Federal Domestic Assistance, No.13.847, Diabetes, Endocrinology, and Metabolic Diseases. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301, (Public Law 78-410), as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations, most specifically at 42 CFR Part 52 and CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

***THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS: 5333 Westbard Avenue
Bethesda, Maryland 20816